Nowadays, tumor immune checkpoint inhibitors (ICIs), including programmed death receptor 1 (PD-1), PD-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have revolutionized NSCLC treatment (1, 2). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.